Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inozyme Pharma, Inc. (NASDAQ: INZY) had its price target lowered by analysts at Bank of America Co. from $16.00 to $14.00. They now have a "buy" rating on the stock.